TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22094904

Group type: EXPERIMENTAL
Intervention: BMMSC treatment
Number of subjects: 100

Group type: COMPARATOR
Intervention: Core decompression (CD) treatment
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: BMMSC treatment and CD treatment
Number of subjects: 100
Study: 20838642

Group type: EXPERIMENTAL
Intervention: SP‐IPTi
Number of subjects: 7
Study: 18757480

Group type: EXPERIMENTAL
Intervention: Exercise + LBNP (Ex-LBNP)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control (Con)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Nutrition (Nut)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Nonfinishers (NF)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Finishers
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Overall
Number of subjects: 24
Study: 17121522

Group type: EXPERIMENTAL
Intervention: Pioglitazone (PGZ)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Metformin (MET)
Number of subjects: 30
Study: 12692844

Group type: EXPERIMENTAL
Intervention: p53 immunostaining (using mouse monoclonal antibody pAb1801)
Number of subjects: 502

Group type: EXPERIMENTAL
Intervention: pT1G3 disease
Number of subjects: 502

Group type: EXPERIMENTAL
Intervention: p53 staining
Number of subjects: 502
Study: 10964288

Group type: EXPERIMENTAL
Intervention: Experimental group treated for all positive antigens
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control group treated for all positive antigens, except study antigens
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Experimental group
Number of subjects: 18
Study: 8858269

Group type: EXPERIMENTAL
Intervention: Buckwheat herb tea (Fagopyrum esculentum)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Placebo tea
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Buckwheat herb tea
Number of subjects: 67
Study: 1516415

Group type: EXPERIMENTAL
Intervention: Indomethacin (50 mg tablets, three times daily for 48 hours prior to testing)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo tablets
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Both Indomethacin and Placebo (during repeated methacholine challenges)
Number of subjects: 10
Study: 6332780

Group type: EXPERIMENTAL
Intervention: Postoperatively administered plasma proteins
Number of subjects: 94

Group type: COMPARATOR
Intervention: Control group (no plasma proteins)
Number of subjects: 94
Study: 31466479

Group type: EXPERIMENTAL
Intervention: External cardioversion
Number of subjects: 230

Group type: COMPARATOR
Intervention: Internal cardioversion
Number of subjects: 230
Study: 30129327

Group type: EXPERIMENTAL
Intervention: Microsurgical approaches (lymphatic‐venous anastomosis (LVA), vascularized lymph node transfer (VLNT))
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conservative treatment
Number of subjects: 0
Study: 27389678

Group type: EXPERIMENTAL
Intervention: SILC using a novel instrument (Group A)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: SILC using a conventional instrument (Group B)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Conventional laparoscopic cholecystectomy (Group C)
Number of subjects: 150
Study: 24901076

Group type: EXPERIMENTAL
Intervention: Low-intensity eccentric contractions with blood flow restriction (BFR)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Low-intensity eccentric contractions without blood flow restriction (BFR)
Number of subjects: 9
Study: 22237175

Group type: EXPERIMENTAL
Intervention: Cytomegalovirus therapeutic DNA vaccine (TransVax) administered before conditioning and at 1, 3, and 6 months after transplantation.
Number of subjects: 108

Group type: COMPARATOR
Intervention: Placebo administered before conditioning and at 1, 3, and 6 months after transplantation.
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Cytomegalovirus therapeutic DNA vaccine (TransVax)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 108
Study: 20609187

Group type: EXPERIMENTAL
Intervention: Step sodium profile
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Linear sodium profile
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control (steady sodium)
Number of subjects: 22
Study: 18343802

Group type: EXPERIMENTAL
Intervention: lopinavir/ritonavir monotherapy
Number of subjects: 21
Study: 15970919

Group type: EXPERIMENTAL
Intervention: Guided imagery technique over a consecutive 4‐day period
Number of subjects: 210

Group type: COMPARATOR
Intervention: Control group (monitored without intervention)
Number of subjects: 210
Study: 12567364

Group type: EXPERIMENTAL
Intervention: General anesthesia with supplementary foot block (0.5% bupivicaine)
Number of subjects: 42

Group type: COMPARATOR
Intervention: General anesthesia alone
Number of subjects: 42
Study: 10616845

Group type: EXPERIMENTAL
Intervention: Dopamine (2 microg/kg per min)
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Furosemide (0.5 microg/kg per min)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Isotonic sodium chloride (placebo)
Number of subjects: 126
Study: 8830827

Group type: EXPERIMENTAL
Intervention: rhuIL‐1R therapy
Number of subjects: 14
Study: 1330678

Group type: EXPERIMENTAL
Intervention: Inhaled nedocromil sodium, 4 mg q.i.d.
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Inhaled beclomethasone dipropionate, 200 micrograms q.i.d.
Number of subjects: 23

Group type: COMPARATOR
Intervention: Comparison of beclomethasone to nedocromil sodium
Number of subjects: 23
Study: 3910302

Group type: EXPERIMENTAL
Intervention: Testosterone undecanoate (TU) 40 mg/d
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Testosterone undecanoate (TU) 80 mg/d
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Testosterone undecanoate (TU) 120 mg/d
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Testosterone undecanoate (TU) 160 mg/d
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Androgen treatment (after 5 months)
Number of subjects: 8
Study: 30316147

Group type: EXPERIMENTAL
Intervention: Lithium
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Valproic acid
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Carbamazepine
Number of subjects: 107

Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 107
Study: 27229908

Group type: EXPERIMENTAL
Intervention: Intranasal dexmedetomidine 2 μg/kg
Number of subjects: 60

Group type: COMPARATOR
Intervention: Intranasal dexmedetomidine 1 μg/kg
Number of subjects: 60
Study: 23812579

Group type: EXPERIMENTAL
Intervention: Prolapse surgery with concurrent tension-free vaginal tape (TVT)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Prolapse surgery alone (no TVT)
Number of subjects: 80
Study: 22549748

Group type: EXPERIMENTAL
Intervention: Negative Pressure Wound Therapy (NPWT)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Standard dry dressing
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Both groups (NPWT and dry dressing)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: NPWT
Number of subjects: 81

Group type: COMPARATOR
Intervention: Dry dressing
Number of subjects: 81
Study: 20138267

Group type: EXPERIMENTAL
Intervention: Serum concentrations of AMH measured on cycle day 3
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: AMH level ≥3.01 ng/mL
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: AMH level ≥3.2 ng/mL
Number of subjects: 60
Study: 19192863

Group type: EXPERIMENTAL
Intervention: Abstinence reinforcement group ($30.00 for each consecutive opioid-free urine sample)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group ($4.00 for completing assessments)
Number of subjects: 22
Study: 15794398

Group type: EXPERIMENTAL
Intervention: Centralized eligibility assessment for MS diagnosis
Number of subjects: 0
Study: 12023995

Group type: EXPERIMENTAL
Intervention: Salmeterol (prophylactic inhalation)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study: 11888456

Group type: EXPERIMENTAL
Intervention: Hypoventilation (tidal volume 4 mL/kg, respiratory rate 15/min)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Normoventilation (tidal volume 10 mL/kg, respiratory rate 10/min)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Hypoventilation
Number of subjects: 80

Group type: COMPARATOR
Intervention: Normoventilation
Number of subjects: 80
Study: 9861280

Group type: EXPERIMENTAL
Intervention: Mectizan (ivermectin) treatment every 3 months
Number of subjects: 1530

Group type: EXPERIMENTAL
Intervention: Mectizan (ivermectin) treatment every 6 months
Number of subjects: 1530

Group type: EXPERIMENTAL
Intervention: Mectizan (ivermectin) treatment every 12 months
Number of subjects: 1530

Group type: COMPARATOR
Intervention: Placebo treatment every 3 months
Number of subjects: 1530
Study: 7622647

Group type: EXPERIMENTAL
Intervention: 5% quaternium‐18 bentonite lotion
Number of subjects: 211

Group type: COMPARATOR
Intervention: Untreated control sites
Number of subjects: 211
Study: 2222900

Group type: EXPERIMENTAL
Intervention: HuIFN alpha (1,200 IU/day)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 342174

Group type: EXPERIMENTAL
Intervention: Low dose fenoterol (5.6 microgram)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Medium dose fenoterol (32.7 microgram)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: High dose fenoterol (127.5 microgram)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo (0 microgram)
Number of subjects: 12
Study: 6356793

Group type: EXPERIMENTAL
Intervention: Nomifensine (150 mg daily)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Amitriptyline (150 mg daily)
Number of subjects: 29
Study: 29226570

Group type: EXPERIMENTAL
Intervention: Sirolimus-based therapy
Number of subjects: 394

Group type: COMPARATOR
Intervention: Tacrolimus-based therapy
Number of subjects: 394
Study: 26546987

Group type: EXPERIMENTAL
Intervention: Power Training (PWT)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: High-Speed Yoga
Number of subjects: 41

Group type: COMPARATOR
Intervention: Control (nonexercise group)
Number of subjects: 41
Study: 23682170

Group type: EXPERIMENTAL
Intervention: Walking training including balance exercises and lower limb strength activities twice a week for 4 months
Number of subjects: 126

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 126
Study: 23153666

Group type: EXPERIMENTAL
Intervention: Fibular fixation (case group)
Number of subjects: 53

Group type: COMPARATOR
Intervention: No fibular fixation (control group)
Number of subjects: 53
Study: 20704266

Group type: EXPERIMENTAL
Intervention: Bead formulation with faster dissolution rate (80% dissolved in 41 min)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bead formulation with slower dissolution rate (80% dissolved in 114 min)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: In vivo bioequivalence study
Number of subjects: 0
Study: 18767577

Group type: EXPERIMENTAL
Intervention: Electroacupuncture plus psychotherapy
Number of subjects: 47

Group type: COMPARATOR
Intervention: Psychotherapy
Number of subjects: 47
Study: 16261102

Group type: EXPERIMENTAL
Intervention: Pulsed electromagnetic field (PEMF) therapy
Number of subjects: 14

Group type: COMPARATOR
Intervention: Galvanic current
Number of subjects: 14

Group type: COMPARATOR
Intervention: Iontophoresis
Number of subjects: 14

Group type: COMPARATOR
Intervention: TENS
Number of subjects: 14

Group type: COMPARATOR
Intervention: PEMF
Number of subjects: 14

Group type: COMPARATOR
Intervention: Diadynamic current
Number of subjects: 14

Group type: COMPARATOR
Intervention: Permanent magnets
Number of subjects: 14

Group type: COMPARATOR
Intervention: Electrical muscle stimulation (EMS)
Number of subjects: 14
Study: 14644633

Group type: EXPERIMENTAL
Intervention: 4,16-androstadien-3-one (androstadienone) exposure (250 microM)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control for sensory detection of the steroid
Number of subjects: 0
Study: 10665727

Group type: EXPERIMENTAL
Intervention: Freeman‐Samuelson hydroxyapatite‐coated (FS HA)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Miller‐Galante II (MG II)
Number of subjects: 38
Study: 9031103

Group type: EXPERIMENTAL
Intervention: Aggressive chemotherapy
Number of subjects: 41
Study: 1341376

Group type: EXPERIMENTAL
Intervention: Ultraviolet irradiation of blood
Number of subjects: 1527
Study: 6375603

Group type: EXPERIMENTAL
Intervention: Proximal anastomoses first
Number of subjects: 30

Group type: COMPARATOR
Intervention: Distal anastomoses first
Number of subjects: 30
Study: 31310354

Group type: EXPERIMENTAL
Intervention: Moderate to severe AAC (AAC24 score >1)
Number of subjects: 1024

Group type: COMPARATOR
Intervention: Low AAC (score 0 and 1)
Number of subjects: 1024
Study: 30028023

Group type: EXPERIMENTAL
Intervention: CD56+ T-ALL
Number of subjects: 493

Group type: EXPERIMENTAL
Intervention: CD56 expression combined with MRD-based high risk assignment
Number of subjects: 493
Study: 27144930

Group type: EXPERIMENTAL
Intervention: Kombiglyze XR (saxagliptin 5 mg/metformin 2000 mg) daily
Number of subjects: 100
Study: 24732081

Group type: EXPERIMENTAL
Intervention: Partial caries removal (PCR)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Total caries removal (TCR)
Number of subjects: 48
Study: 22984089

Group type: EXPERIMENTAL
Intervention: Adapted games (AG)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo activities (PL)
Number of subjects: 20
Study: 20499150

Group type: EXPERIMENTAL
Intervention: HIV positive women
Number of subjects: 535

Group type: EXPERIMENTAL
Intervention: HIV positive men
Number of subjects: 535

Group type: COMPARATOR
Intervention: HIV negative men
Number of subjects: 535

Group type: EXPERIMENTAL
Intervention: Couples overall
Number of subjects: 535
Study: 18620577

Group type: EXPERIMENTAL
Intervention: AS+AQ
Number of subjects: 227

Group type: COMPARATOR
Intervention: AM-L
Number of subjects: 227
Study: 15951679

Group type: EXPERIMENTAL
Intervention: Printed questionnaire
Number of subjects: 875

Group type: COMPARATOR
Intervention: Web questionnaire with personalized feedback
Number of subjects: 875

Group type: COMPARATOR
Intervention: Plain Web questionnaire
Number of subjects: 875
Study: 12532169

Group type: EXPERIMENTAL
Intervention: Statin therapy initiated early after acute coronary syndrome
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Statin therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Statin therapy prescribed during initial hospitalization for ACS
Number of subjects: 0
Study: 10583717

Group type: EXPERIMENTAL
Intervention: Lower body negative pressure (LBNP) 15 cmH2O
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Lower body negative pressure (LBNP) 30 cmH2O
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Lower body negative pressure (LBNP) 60 cmH2O
Number of subjects: 24
Study: 9062806

Group type: EXPERIMENTAL
Intervention: Peak Expiratory Flow Rate (PEFR) measurement
Number of subjects: 1315
Study: 1874765

Group type: EXPERIMENTAL
Intervention: Tourniquet inflated throughout the procedure, released postoperatively after compressive dressing; splint used for three days (Group I)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Tourniquet inflated throughout the procedure, no splint, continuous passive motion started immediately (Group II)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Tourniquet released intraoperatively, hemostasis by cauterization, compressive dressing applied, splint used for three days (Group III)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Tourniquet released intraoperatively, reinflated after hemostasis, compressive dressing applied, continuous passive motion started immediately (Group IV)
Number of subjects: 121
Study: 7103152

Group type: EXPERIMENTAL
Intervention: Aerosolized nasal dexamethasone phosphate
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study: 29665620

Group type: EXPERIMENTAL
Intervention: Anti-inflammatory nutrition supplement (AINS) consisting of long chain n-3 PUFA, vitamin C, α-tocopherol, green tea extract, and lycopene for 8 weeks
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo for 8 weeks
Number of subjects: 70
Study: 26944021

Group type: EXPERIMENTAL
Intervention: Nicotine nasal spray (1mg per dose, up to 40 times per day)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Varenicline (2mg/day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo nicotine nasal spray
Number of subjects: 0

Group type: COMPARATOR
Intervention: Varenicline placebo
Number of subjects: 0
Study: 24744188

Group type: EXPERIMENTAL
Intervention: 2-m biliopancreatic (BP)-limb and a 60-cm alimentary (A)-limb (n=93)
Number of subjects: 187

Group type: COMPARATOR
Intervention: 150-cm A-limb and a 60-cm BP-limb (n=94)
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: 2-m BP-limb group
Number of subjects: 187

Group type: COMPARATOR
Intervention: 150-cm A-limb group
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 187
Study: 23114512

Group type: EXPERIMENTAL
Intervention: Enema
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Lubricant-filled applicator
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Suppository
Number of subjects: 117
Study: 20739719

Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate (NaHCO₃) 0.3 g/kg body weight
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 19052191

Group type: EXPERIMENTAL
Intervention: Family-centered electronic media intervention; 20-week duration; included setting electronic media use goals, using TV Allowance device and ENUFF software.
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control group; no specific intervention mentioned.
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Family-centered electronic media intervention; 20-week duration.
Number of subjects: 21
Study: 15836964

Group type: EXPERIMENTAL
Intervention: IBS patients
Number of subjects: 21

Group type: COMPARATOR
Intervention: Healthy female controls
Number of subjects: 21
Study: 12580842

Group type: EXPERIMENTAL
Intervention: Women with BMI > 25 and polycystic ovaries
Number of subjects: 68

Group type: COMPARATOR
Intervention: Women with BMI ≤ 25 and normal ovaries
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Women with BMI ≤ 25 and polycystic ovaries
Number of subjects: 68

Group type: COMPARATOR
Intervention: Women with BMI > 25 and normal ovaries
Number of subjects: 68
Study: 10506264

Group type: EXPERIMENTAL
Intervention: Acetaminophen (12 mg/kg)
Number of subjects: 27065

Group type: EXPERIMENTAL
Intervention: Ibuprofen (5 mg/kg)
Number of subjects: 27065

Group type: EXPERIMENTAL
Intervention: Ibuprofen (10 mg/kg)
Number of subjects: 27065

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 27065
Study: 8699065

Group type: EXPERIMENTAL
Intervention: FLA‐ELISA followed by immunoblotting
Number of subjects: 0
Study: 1911501

Group type: EXPERIMENTAL
Intervention: 5-mg MS bolus and subsequent saline infusion (n = 13)
Number of subjects: 31

Group type: COMPARATOR
Intervention: 2.6-mg MS bolus and subsequent MS infusion at 0.1 mg/hour (n = 18)
Number of subjects: 31
Study: 7036092

Group type: EXPERIMENTAL
Intervention: Long-acting secretin in doses of 10 clinical units twice daily
Number of subjects: 100
Study: 31982847

Group type: EXPERIMENTAL
Intervention: MAP maintained from baseline to 10% above the baseline (group H)
Number of subjects: 150

Group type: COMPARATOR
Intervention: MAP maintained from 10% to 20% below the baseline (group D)
Number of subjects: 150

Group type: COMPARATOR
Intervention: MAP maintained from baseline to 10% below the baseline (group M)
Number of subjects: 150
Study: 30896643

Group type: EXPERIMENTAL
Intervention: Allisartan isoproxil
Number of subjects: 80

Group type: COMPARATOR
Intervention: Nifedipine
Number of subjects: 80
Study: 29140929

Group type: EXPERIMENTAL
Intervention: Acute nociceptive low back pain induced by saline injection
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham injection (nocebo pain)
Number of subjects: 0

Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 0
Study: 25524125

Group type: EXPERIMENTAL
Intervention: Chewing gum
Number of subjects: 120

Group type: COMPARATOR
Intervention: Dermal patch (control)
Number of subjects: 120
Study: 23695501

Group type: EXPERIMENTAL
Intervention: FACETS plus current local practice (FACETS)
Number of subjects: 164

Group type: COMPARATOR
Intervention: Current local practice alone (CLP)
Number of subjects: 164
Study: 21872244

Group type: EXPERIMENTAL
Intervention: 600 μg of oral misoprostol
Number of subjects: 242

Group type: COMPARATOR
Intervention: Manual vacuum aspiration (MVA)
Number of subjects: 242
Study: 19485583

Group type: EXPERIMENTAL
Intervention: Supervisor focus on adherence to treatment principles
Number of subjects: 1979

Group type: EXPERIMENTAL
Intervention: Adherence to the Structure and Process of Supervision
Number of subjects: 1979

Group type: EXPERIMENTAL
Intervention: Focus on Clinician Development
Number of subjects: 1979
Study: 17214933

Group type: EXPERIMENTAL
Intervention: Traditional Chinese herbal medicine (CM) including Glucosidorum Tripterygii Totorum Tablet and syndrome differentiation treatment
Number of subjects: 397

Group type: COMPARATOR
Intervention: Western medicine (WM) including voltaren extended action tablet, methotrexate, and sulfasalazine
Number of subjects: 397

Group type: EXPERIMENTAL
Intervention: Neural network model analysis
Number of subjects: 397
Study: 15266634

Group type: EXPERIMENTAL
Intervention: 1-mA bipolar, binaural galvanic vestibular stimulation (GVS) triggered prior to plantarflexor activity
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no GVS)
Number of subjects: 0
Study: 11319627

Group type: EXPERIMENTAL
Intervention: Active Ma Huang/Guarana (72 mg/day ephedrine alkaloids and 240 mg/day caffeine)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Active Ma Huang/Guarana
Number of subjects: 67
Study: 9595179

Group type: EXPERIMENTAL
Intervention: Stress-management training (education, relaxation, and problem-solving training)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Waiting list control group
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Stress-management training (self-measured BP)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Stress-management training (4-month follow-up)
Number of subjects: 43
Study: 7636666

Group type: EXPERIMENTAL
Intervention: Fluconazole suspension, 2 to 3 mg/kg per day
Number of subjects: 182

Group type: COMPARATOR
Intervention: Nystatin, 400,000 units four times daily for 14 days
Number of subjects: 182
Study: 2794994

Group type: EXPERIMENTAL
Intervention: Moclobemide 600 mg/d
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Imipramine 200 mg/d
Number of subjects: 75

Group type: COMPARATOR
Intervention: Placebo (6 caps/d)
Number of subjects: 75